TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE D-

NCT06780137: A Phase 1b/2 Open-Label Clinical Study to Evaluate the Safety and Efficacy of MK-6070 and Ifinatamab Deruxtecan (I-DXd) in Participants With Relapsed/Refractory Extensive-Stage Small Cell Lung Cancer

Sponsor: Merck Sharp & Dohme LLC · Phase: PHASE1/PHASE2 · Area: ONCOLOGY · Target Enrollment: 327 pts

Competing Trials Overlap

6 Active Trials

Excess Burn Exposure

$7,971,810

Rescue Site Savings

+$5,262,180

Unlock Full NCT06780137 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06780137 Rescue Dossier →